 LONDON and NEW YORK, Nov. 18, 2020 GLOBE NEWSWIRE -- MeiraGTx Holdings plc NASDAQ:MGTX, a vertically integrated, clinical stage gene therapy company, today announced that it has commenced an underwritten public offering of 5,000,000 of its ordinary shares. In connection with the offering, MeiraGTx intends to grant the underwriters a 30-day option to purchase up to an additional 750,000 of its ordinary shares. All of the ordinary shares are being offered by MeiraGTx. 